

[40, 30-39, 21, 29, 28, 27, 26, 25, 24, 23, 22, 10-20, 4, 3, 2, 9, 8, 7, 6, 5, 1]

2009

1. Davis, I.D., Brady, B., Kefford, R.F., Millward, M., Cebon, J., Skrumsager, B.K., Mouritzen, U., Hansen, L.T., Skak, K., Lundsgaard, D., Frederiksen, K.S., Kristjansen, P.E., and McArthur, G., Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. *Clin Cancer Res*, 15(6): p. 2123-9 2009.
2. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of ¹⁷⁷Lu-CHX-A"-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. *Prostate*, 69(1): p. 92-104 2009.
3. Gedye, C., Quirk, J., Browning, J., Svobodova, S., John, T., Sluka, P., Dunbar, P.R., Corbeil, D., Cebon, J., and Davis, I.D., Cancer/testis antigens can be immunological targets in clonogenic CD133(+) melanoma cells. *Cancer Immunol Immunother*, 2009.
4. Ebert, L.M., Liu, Y.C., Clements, C.S., Robson, N.C., Jackson, H.M., Markby, J.L., Dimopoulos, N., Tan, B.S., Luescher, I.F., Davis, I.D., Rossjohn, J., Cebon, J., Purcell, A.W., and Chen, W., A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. *Cancer Res*, 69(3): p. 1046-54 2009.
5. Watson, A.J., Middleton, M.R., MCGown, G., Thorncroft, M., Ranson, M., Hersey, P., McArthur, G., Davis, I.D., Thomson, D., Beith, J., Haydon, A., Kefford, R., Lorigan, P., Mortimer, P., Sabharwal, A., Hayward, O., and Margison, G.P., O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. *Br J Cancer*, 100(8): p. 1250-6 2009.
6. Pezaro, C., Rosenthal, M.A., Gurney, H., Davis, I.D., Underhill, C., Boyer, M.J., Kotasek, D., Solomon, B., and Toner, G.C., An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. *Am J Clin Oncol*, 2009.
7. Nicholaou, T., Ebert, L.M., Davis, I.D., McArthur, G.A., Jackson, H., Dimopoulos, N., Tan, B., Maraskovsky, E., Miloradovic, L., Hopkins, W., Pan, L., Venhaus, R., Hoffman, E.W., Chen, W., and Cebon, J., Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. *Clin Cancer Res*, 15(6): p. 2166-2173 2009.
8. Lawrentschuk, N., Lee, F.T., Jones, G., Rigopoulos, A., Mountain, A., O'keefe, G., Papenfuss, A.T., Bolton, D.M., Davis, I.D., and Scott, A.M., Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. *Urol Oncol*, 2009.
9. Klein, O., Ebert, L.M., Nicholaou, T., Browning, J., Russell, S.E., Zuber, M., Jackson, H.M., Dimopoulos, N., Tan, B.S., Hoos, A., Luescher, I.F., Davis, I.D., Chen, W., and Cebon, J., Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. *Clin Cancer Res*, 15(7): p. 2507-13 2009.

2008

10. Davis, I.D., Advances in the Treatment of Castrate-resistant Prostate Cancer. *Asia-Pacific Oncology & Haematology*, 1: p. 52-55 2008.
11. Zalcborg, J.R., Rosen, L.S., Abdi, E., Davis, I.D., Gutheil, J., Schnell, F.M., Cesano, A., Gayko, U., Chen, M.G., and Clarke, S., Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer. *J Clin Oncol*, 26(8): p. 1386-7 2008.
12. Pezaro, C. and Davis, I.D., Targeted therapies in the treatment of renal cell carcinoma. *Curr Med Chem*, 15(12): p. 1166-74 2008.
13. Lawrentschuk, N., Appu, S., Chao, I., Chan, Y., Rogerson, J., and Davis, I.D., Peripheral primitive neuroectodermal tumor arising from the seminal vesicle. *Urol Int*, 80(2): p. 212-5; discussion 216 2008.
14. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of (177)Lu-CHX-A"-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. *Prostate*, 2008.
15. John, T., Caballero, O.L., Svobodova, S.J., Kong, A., Chua, R., Browning, J., Fortunato, S., Deb, S., Hsu, M., Gedye, C.A., Davis, I.D., Altorki, N., Simpson, A.J., Chen, Y.T., Monk, M., and Cebon, J.S., ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. *Clin Cancer Res*, 14(11): p. 3291-8 2008.
16. John, T., Black, M.A., Toro, T.T., Leader, D., Gedye, C.A., Davis, I.D., Guilford, P.J., and Cebon, J.S., Predicting clinical outcome through molecular profiling in stage III melanoma. *Clin Cancer Res*, 14(16): p. 5173-80 2008.
17. Grossmann, M., Premaratne, E., Desai, J., and Davis, I.D., Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. *Clin Endocrinol (Oxf)*, 69: p. 669-672 2008.
18. Frederiksen, K.S., Lundsgaard, D., Freeman, J.A., Hughes, S.D., Holm, T.L., Skrumsager, B.K., Petri, A., Hansen, L.T., McArthur, G.A., Davis, I.D., and Skak, K., IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. *Cancer Immunol Immunother*, 57(10): p. 1439-49 2008.
19. Ebert, L.M., Tan, B.S., Browning, J., Svobodova, S., Russell, S.E., Kirkpatrick, N., Gedye, C., Moss, D., Ng, S.P., Macgregor, D., Davis, I.D., Cebon, J., and Chen, W., The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. *Cancer Res*, 68(8): p. 3001-9 2008.
20. Davis, I.D. and Desai, J., Clinical use of therapies targeting tumor vasculature and stroma. *Curr Cancer Drug Targets*, 8(6): p. 498-508 2008.

2007

21. Cebon, J., Gedye, C., John, T., and Davis, I.D., Immunotherapy of advanced or metastatic melanoma. *Clinical Advances in Hematology & Oncology*, 5(12): p. 994-1006 2007.

22. Scott, A.M., Tebbutt, N., Lee, F.T., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A.M., Hopkins, W., Smyth, F.E., Murone, C., Macgregor, D., Papenfuss, A.T., Chappell, B., Saunder, T.H., Brechbiel, M.W., Davis, I.D., Murphy, R., Chong, G., Hoffman, E.W., and Old, L.J., A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. *Clin Cancer Res*, 13(11): p. 3286-92 2007.
23. Nicholaou, T., Wong, R., and Davis, I.D., Tumour lysis syndrome in a patient with renal cell carcinoma treated with sunitinib malate. *The Lancet*, 369: p. 1923-1924 2007.
24. Lawrentschuk, N., Davis, I.D., Bolton, D.M., and Scott, A.M., Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. *Int J Urol*, 14(2): p. 89-95 2007.
25. Lawrentschuk, N., Bolton, D.M., Davis, I.D., and Scott, A.M., Renal Cell Cancer and Positron Emission Tomography- an evolving diagnostic and therapeutic relationship. *Current Medical Imaging Reviews*, 3(1): p. 17-26 2007.
26. Davis, I.D., Wiseman, G.A., Lee, F.T., Gansen, D.N., Hopkins, W., Papenfuss, A.T., Liu, Z., Moynihan, T.J., Croghan, G.A., Adjei, A.A., Hoffman, E.W., Ingle, J.N., Old, L.J., and Scott, A.M., A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. *Cancer Immun*, 7: p. 13 2007.
27. Davis, I.D., Skak, K., Smyth, M.J., Kristjansen, P.E., Miller, D.M., and Sivakumar, P.V., Interleukin-21 signaling: functions in cancer and autoimmunity. *Clin Cancer Res*, 13(23): p. 6926-32 2007.
28. Davis, I.D., Liu, Z., Saunders, W., Lee, F.T., Spirkoska, V., Hopkins, W., Smyth, F.E., Chong, G., Papenfuss, A.T., Chappell, B., Poon, A., Saunder, T.H., Hoffman, E.W., Old, L.J., and Scott, A.M., A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. *Cancer Immun*, 7: p. 14 2007.
29. Chew, S.F., Wood, B.R., Kanaan, C., Browning, J., Macgregor, D., Davis, I.D., Cebon, J., Tait, B.D., and Mcnaughton, D., Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody. *Tissue Antigens*, 69 Suppl 1: p. 252-8 2007.

2006

30. Lim, E., Browning, J., Macgregor, D., Davis, I.D., and Cebon, J.S., Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. *Melanoma Res*, 16(4): p. 347-55 2006.
31. Lawrentschuk, N., Rigopoulos, A., Lee, F.T., Davis, I.D., Scott, A.M., and Bolton, D.M., Xenografting tumour beneath the renal capsule using modern surgical equipment. *Eur Surg Res*, 38(3): p. 340-6 2006.
32. Lawrentschuk, N., Davis, I.D., Bolton, D.M., and Scott, A.M., Positron emission tomography and molecular imaging of the prostate: an update. *BJU Int*, 97(5): p. 923-31 2006.

33. Lawrentschuk, N., Davis, I.D., Bolton, D.M., and Scott, A.M., Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. *BJU Int*, 97(5): p. 916-22 2006.
34. Jackson, H., Dimopoulos, N., Mifsud, N.A., Tai, T.Y., Chen, Q., Svobodova, S., Browning, J., Luescher, I., Stockert, L., Old, L.J., Davis, I.D., Cebon, J., and Chen, W., Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. *J Immunol*, 176(10): p. 5908-17 2006.
35. Goldstein, D., Ackland, S.P., Bell, D.R., Olver, I.N., Davis, I.D., Rosenthal, M.A., Toner, G.C., Pinel, M.C., and Byrne, M., Phase II study of vinflunine in patients with metastatic renal cell carcinoma. *Invest New Drugs*, 24(5): p. 429-34 2006.
36. Gan, H.K., Mitchell, P.L., Galettis, P., Davis, I.D., Cebon, J., De Souza, P., and Links, M., A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. *Cancer Chemother Pharmacol*, 58(2): p. 157-64 2006.
37. Davis, I.D., Chen, Q., Morris, L., Quirk, J., Stanley, M., Tavarnesi, M.L., Parente, P., Cavicchiolo, T., Hopkins, W., Jackson, H., Dimopoulos, N., Tai, T.Y., Macgregor, D., Browning, J., Svobodova, S., Caron, D., Maraskovsky, E., Old, L.J., Chen, W., and Cebon, J., Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. *J Immunother*, 29(5): p. 499-511 2006.
38. Barrow, C., Browning, J., Macgregor, D., Davis, I.D., Sturrock, S., Jungbluth, A.A., and Cebon, J., Tumor antigen expression in melanoma varies according to antigen and stage. *Clin Cancer Res*, 12(3 Pt 1): p. 764-71 2006.
39. Nicholaou, T., Ebert, L., Davis, I.D., Robson, N., Klein, O., Maraskovsky, E., Chen, W., and Cebon, J., Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. *Immunol Cell Biol*, 84(3): p. 303-17 2006.
40. Rosen, L.S., Abdi, E., Davis, I.D., Gutheil, J., Schnell, F.M., Zalberg, J., Cesano, A., Gayko, U., Chen, M.G., and Clarke, S., Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. *J Clin Oncol*, 2006.

2005

41. Chong G., Lee F-T., Hopkins W., Tebbutt N.C., Cebon J.S., Mountain A., Chappell B, Papenfuss A., Schleyer P, U P.L., Murphy R., Wirth V, Smyth F., Potasz N, Poon A., Davis I.D., Saunder T, O'Keefe GJ, Burgess A.W., Hoffman E.W., Old L.J., and Scott A.M. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma. *Clinical Cancer Research*. 11 (13): 4818-26, 2005.
42. Scott A.M., Liu Z., Murone C., Johns T.G., MacGregor D., Smyth F.E., Lee F-T., Cebon J., Davis I.D., Hopkins W., Mountain A., Rigopoulos A., Hanai N., and Old L.J. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. *Cancer Immunity*. 5: 3 2005.
43. John T., Cebon J.S., and Davis I.D. Biochemotherapy for the treatment of metastatic melanoma: the experience of a tertiary oncology center. *Asia - Pacific Journal of Clinical Oncology*. 1: 81-7 2005.

44. Chen Q., Jackson H., Shackleton M., Parente P, Hopkins W., Sturrock S., MacGregor D., Maraskovsky E., Tai T.Y., Dimopoulos N, Masterman K-A., Luke T., Davis I.D., Chen W., and Cebon J. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. *Cancer Immunity*. 5: 5-12, 2005.
 45. John T., and Davis I.D. Ventricular metastasis resulting in disseminated intravascular coagulation. *World Journal of Surgical Oncology*. 3: 29-32, 2005.
-

2004

46. Schnurr M., Toy T, Shin A., Hartmann G, Rothenfusser S., Soellner J., Davis I.D., Cebon J.S., and Maraskovsky E. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. *Blood*. 103 (4): 1391-7, 2004.
47. Jefford M., Michael M., Rosenthal M.A., Davis I.D., Green M., McClure M., Smith J., Waite B., and Zalberg J. A novel combination of Cisplatin, irinotecan, and capecitabine in patients with advanced cancer. *Investigational new drugs*. 22 (2): 185-92, 2004.
48. Shackleton M., Davis I.D., Hopkins W., Jackson H., Dimopoulos N, Tai T.Y., Chen Q., Parente P, Jefford M., Masterman K-A., Caron D, Chen W., Maraskovsky E., and Cebon J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. *Cancer Immunity*. 4:9-21(2004)
49. Jackson H.M., Dimopoulos N, Chen Q., Luke T., Yee Tai T., Maraskovsky E., Old L.J., Davis I.D., Cebon J., and Chen W. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. *Journal of immunological methods*. 291 (1-2): 51-62, 2004.
50. Putra L.J., Lawrentschuk N., Ballok Z., Hannah A., Poon A., Tauro A., Davis I.D., Hicks R.J., Bolton D.M., and Scott A.M. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. *Urology*. 64 (6): 1202-7, 2004.
51. Mitchell P.L., Basser R.L., Chipman M., Grigg A., Mansfield R., Cebon J., Davis I.D., Appel F., and Green M. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. *Annals of Oncology*. 15 (4): 585-9, 2004.
52. Jefford M., Kiffer J.D., Somers G., Daniel F.J., and Davis I.D. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. *Australian and New Zealand Journal of Surgery*. 74 (8): 704-5, 2004.
53. Vaughan H.A., Svobodova S., MacGregor D., Jungbluth A.A., Browning J., Davis I.D., Parente P, Chen Y.T., Stockert E., Old L.J., and Cebon J. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. *Clinical Cancer Research*. 10 (24): 8396-404, 2004.
54. Schnurr M., Chen Q., Shin A., Chen W., Toy T, Jenderek C., Green S., Miloradovic L., Drane D., Davis I.D., Villadangos J., Shortman K., Maraskovsky E., and Cebon J. Tumor antigen processing and presentation depends critically on dendritic cell type and the mode of antigen delivery. *Blood* 2004 Nov 16; 105 (6): 2465-2472, 2004.